Search | Clinical Trials Finder

Conditions: Chikungunya Virus Infection
Interventions: VLA1553; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 10
States / cities: Phoenix, Arizona • Hallandale, Florida • Chicago, Illinois + 7 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 2 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Herpes Labialis
Interventions: onabotulinumtoxinA, Bacteriostatic normal saline; Drug · Other
Lead sponsor: DeNova Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Interventions: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Alabaster, Alabama • Sacramento, California • Jacksonville, Florida + 4 more

Conditions: Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions: Not listed
Lead sponsor: Karius, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dengue
Interventions: V180, Alhydrogel™, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
Interventions: Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine; Dietary Supplement · Biological
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Davis, California

Conditions: Typhoid Fever
Interventions: BB IND 6989; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Long COVID
Interventions: Heat therapy, Sham Control, Walking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 90 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Typhoid Fever
Interventions: Vivotif; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dengue Fever
Interventions: Tetravalent Dengue Vaccine (TDV); Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Anaheim, California • Hutchinson, Kansas

Conditions: Cough, Myalgia, Nasal Obstruction, Sore Throat, Headache, Fatigue, Fever
Interventions: Not listed
Lead sponsor: Cellex, Inc.; Industry
Eligibility: Not listed
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland

Conditions: Typhoid Fever
Interventions: Ty800 (Salmonella typhi) Oral Vaccine; Biological
Lead sponsor: Avant Immunotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Healthy Volunteers, Dengue, Human Challenge Trial
Interventions: rDEN2delta30-7169; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Febrile Neutropenia
Interventions: linezolid, vancomycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 16
States / cities: Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more

Conditions: Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus, Ebolavirus
Interventions: VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dengue
Interventions: rDEN3/4delta30(ME), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Neutropenia, Infection
Interventions: CLT-008, G-CSF; Biological
Lead sponsor: Cellerant Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Typhoid
Interventions: Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4), Placebo (Cohorts 1-4 pooled); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: South Miami, Florida • Baltimore, Maryland • Burlington, Vermont

Conditions: Dengue
Interventions: TV005, Placebo, rDEN2∆30-7169; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Dengue
Interventions: YF-17D, TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more

Conditions: Dengue
Interventions: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Syracuse, New York

Search by objective public record fields.

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Botulinum Toxin A for Herpes Labialis

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine

Heat thErapy And mobiLity in COVID-19 Survivors

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Clinical Evaluation of QFlu Combo Test

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Ebola and Marburg Virus Vaccines

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain